Strata Critical Medical, Inc. beat EPS estimates 81% of the time across 16 reported quarters (13 beats, 3 misses), averaging +15.2% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.01 | $-0.01 | +0.0% | Beat | Q2 FY26 call |
| Q1 FY26 | not reported | $0.03 | not reported | not reported | |
| Q4 FY25 | not reported | $-0.07 | not reported | not reported | |
| Q3 FY25 | not reported | $-0.06 | not reported | not reported | |
| Q2 FY25 | $-0.04 | $-0.05 | -25.0% | Miss | |
| Q1 FY25 | not reported | $-0.04 | not reported | not reported | |
| Q4 FY24 | $-0.12 | $-0.12 | +0.0% | Beat | |
| Q3 FY24 | $-0.06 | $-0.03 | +50.0% | Beat | |
| Q2 FY24 | $-0.06 | $-0.06 | +0.0% | Beat | |
| Q1 FY24 | $-0.13 | $-0.06 | +53.9% | Beat | |
| Q4 FY23 | $-0.13 | $-0.23 | -76.9% | Miss | |
| Q3 FY23 | $-0.10 | $0.00 | +100.0% | Beat |
Back to SRTA overview · SRTA holders · SRTA KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.